Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial

Rituximab vs Low-Dose Mycophenolate Mofetil In Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults

(2021) Pietro Ravani et al.   JAMA Pediatrics

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

(2020) Khalaf Kridin et al.   AUTOIMMUNITY REVIEWS

Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial

(2020) Pietro Ravani et al.   PEDIATRIC NEPHROLOGY

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

(2020) Lionel Rougé et al.   SCIENCE

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

(2020) Sonia Boyer-Suavet et al.   Frontiers in Immunology

Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study

(2020) Pietro Ravani et al.   PEDIATRIC NEPHROLOGY

Binding mechanisms of therapeutic antibodies to human CD20

(2020) Anand Kumar et al.   SCIENCE

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy

(2020) David G. Maloney et al.   Blood Advances

Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus

(2019) Chris Wincup et al.   ANNALS OF THE RHEUMATIC DISEASES

Atypical IgM on T cells predict relapse and steroid-dependence in idiopathic nephrotic syndrome

(2019) Manuela Colucci et al.   KIDNEY INTERNATIONAL

Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes

(2019) Eugene Yu-hin Chan et al.   KIDNEY INTERNATIONAL

Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome

(2018) Alice Bonanni et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice

(2018) Agnès Jamin et al.   JOURNAL OF AUTOIMMUNITY

Idiopathic nephrotic syndrome in children

(2018) Damien G Noone et al.   LANCET

Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome

(2018) Divya Bhatia et al.   PEDIATRIC RESEARCH

Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study

(2018) Toshiyuki Takahashi et al.   PEDIATRIC NEPHROLOGY

Ofatumumab for the treatment of childhood nephrotic syndrome

(2017) Chia-Shi Wang et al.   PEDIATRIC NEPHROLOGY

Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol

(2017) Pietro Ravani et al.   BMJ Open

Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab

(2016) Marina Vivarelli et al.   PEDIATRIC NEPHROLOGY

Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children

(2015) P. Ravani et al.   Clinical Journal of the American Society of Nephrology

B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome

(2015) M. Colucci et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial

(2015) P. Ravani et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial

(2014) Kazumoto Iijima et al.   LANCET

Ofatumumab for Rituximab-Resistant Nephrotic Syndrome

(2014) Biswanath Basu   NEW ENGLAND JOURNAL OF MEDICINE

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

(2014) M. Delville et al.   Science Translational Medicine

Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor–dependent idiopathic nephrotic syndrome

(2013) Pietro Ravani et al.   KIDNEY INTERNATIONAL

Chapter 5: Minimal-change disease in adults

(2012)   Kidney International Supplements

Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome: A Randomized Controlled Trial

(2011) P. Ravani et al.   Clinical Journal of the American Society of Nephrology

Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study

(2010) F. C. Fervenza et al.   Clinical Journal of the American Society of Nephrology

Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children

(2009) H. A.C. Kyrieleis et al.   Clinical Journal of the American Society of Nephrology